Cost-effective choice of antimicrobial therapy for serious infections (Q39592533)

13 September 2017

Cost-effective choice of antimicrobial therapy for serious infections (English)

1 reference

13 September 2017

M C Weinstein

1

1 reference

13 September 2017

J L Read

2

1 reference

13 September 2017

D N MacKay

3

1 reference

13 September 2017

J J Kresel

4

1 reference

13 September 2017

H Ashley

5

1 reference

13 September 2017

K T Halvorsen

6

1 reference

13 September 2017

H C Hutchings

7

1 reference

13 September 2017

1 November 1986

1 reference

Journal of General Internal Medicine

13 September 2017

1 reference

13 September 2017

1

1 reference

13 September 2017

6

1 reference

13 September 2017

351-363

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02596417

13 September 2017

0 references

cites work

Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides

1 reference

https://api.crossref.org/works/10.1007%2FBF02596417

Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02596417

Primary, Secondary, and Meta-Analysis of Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02596417

Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02596417

Fallacy of the five-year survival in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02596417

Identifying costs of medical care. An essential step in allocating resources

21 January 2018

1 reference

12 December 2020

A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis

1 reference

12 December 2020

Management of pneumonia in the prospective payment era. A need for more clinician and support service interaction

1 reference

12 December 2020

Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections

1 reference

12 December 2020

New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations

1 reference

12 December 2020

Risk of infection after penetrating abdominal trauma

1 reference

12 December 2020

Prospective, randomized, double-blind comparison of metronidazole and tobramycin with clindamycin and tobramycin in the treatment of intra-abdominal sepsis

1 reference

12 December 2020

A Randomized Clinical Trial of Moxalactam Alone versus Tobramycin plus Clindamycin in Abdominal Sepsis

1 reference

12 December 2020

Clindamycin-associated colitis. A prospective study

1 reference

12 December 2020

Nosocomial lung infection and its diagnosis

1 reference

12 December 2020

The clinical microbiology laboratory. Utilization and cost-effectiveness

1 reference

12 December 2020

Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock

1 reference

12 December 2020

Reporting on methods in clinical trials

1 reference

12 December 2020

A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections

1 reference

12 December 2020

Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra-abdominal infection

1 reference

12 December 2020

Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft-tissue surgical sepsis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02596417

1 reference

13 September 2017

1 reference